Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 in adolescent atopic dermatitis
NCT06765005Phase 2Recruiting
- Sponsor
- Hunan Mabgeek Biotechnology
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of comekibart in atopic dermatitis (AD), sponsored by Hunan Mabgeek Biotechnology. Started Jul 2024; status: recruiting.
02
Drugs
comekibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06765005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765005.